Literature DB >> 33742144

Development of a rational strategy for integration of lactate dehydrogenase A suppression into therapeutic algorithms for head and neck cancer.

Yunyun Chen1, Anastasios Maniakas1,2, Lin Tan3, Meng Cui1,4, Xiangdong Le1, Joshua S Niedzielski5, Keith A Michel5, Collin J Harlan5, Wuhao Lu6,7, Ying C Henderson1, Abdallah S R Mohamed8,9, Philip L Lorenzi3, Nagireddy Putluri10, James A Bankson5, Vlad C Sandulache11, Stephen Y Lai12,13,14.   

Abstract

BACKGROUND: Lactate dehydrogenase (LDH) is a critical metabolic enzyme. LDH A (LDHA) overexpression is a hallmark of aggressive malignancies and has been linked to tumour initiation, reprogramming and progression in multiple tumour types. However, successful LDHA inhibition strategies have not materialised in the translational and clinical space. We sought to develop a rational strategy for LDHA suppression in the context of solid tumour treatment.
METHODS: We utilised a doxycycline-inducible short hairpin RNA (shRNA) system to generate LDHA suppression. Lactate and LDH activity levels were measured biochemically and kinetically using hyperpolarised 13C-pyruvate nuclear magnetic resonance spectroscopy. We evaluated effects of LDHA suppression on cellular proliferation and clonogenic survival, as well as on tumour growth, in orthotopic models of anaplastic thyroid carcinoma (ATC) and head and neck squamous cell carcinoma (HNSCC), alone or in combination with radiation.
RESULTS: shRNA suppression of LDHA generated a time-dependent decrease in LDH activity with transient shifts in intracellular lactate levels, a decrease in carbon flux from pyruvate into lactate and compensatory shifts in metabolic flux in glycolysis and the Krebs cycle. LDHA suppression decreased cellular proliferation and temporarily stunted tumour growth in ATC and HNSCC xenografts but did not by itself result in tumour cure, owing to the maintenance of residual viable cells. Only when chronic LDHA suppression was combined with radiation was a functional cure achieved.
CONCLUSIONS: Successful targeting of LDHA requires exquisite dose and temporal control without significant concomitant off-target toxicity. Combinatorial strategies with conventional radiation are feasible as long as the suppression is targeted, prolonged and non-toxic.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33742144      PMCID: PMC8110762          DOI: 10.1038/s41416-021-01297-x

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   9.075


  48 in total

Review 1.  Glucose metabolism in cancer cells.

Authors:  Alessandro Annibaldi; Christian Widmann
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2010-07       Impact factor: 4.294

Review 2.  mTOR links oncogenic signaling to tumor cell metabolism.

Authors:  Jessica L Yecies; Brendan D Manning
Journal:  J Mol Med (Berl)       Date:  2011-02-08       Impact factor: 4.599

3.  Targeting Glycolysis through Inhibition of Lactate Dehydrogenase Impairs Tumor Growth in Preclinical Models of Ewing Sarcoma.

Authors:  Choh Yeung; Anna E Gibson; Sameer H Issaq; Nobu Oshima; Joshua T Baumgart; Leah D Edessa; Ganesha Rai; Daniel J Urban; Michelle S Johnson; Gloria A Benavides; Giuseppe L Squadrito; Marielle E Yohe; Haiyan Lei; Sandy Eldridge; John Hamre; Tyrone Dowdy; Victor Ruiz-Rodado; Adrian Lita; Arnulfo Mendoza; Jack F Shern; Mioara Larion; Lee J Helman; Gordon M Stott; Murali C Krishna; Matthew D Hall; Victor Darley-Usmar; Leonard M Neckers; Christine M Heske
Journal:  Cancer Res       Date:  2019-08-20       Impact factor: 12.701

Review 4.  Why do cancers have high aerobic glycolysis?

Authors:  Robert A Gatenby; Robert J Gillies
Journal:  Nat Rev Cancer       Date:  2004-11       Impact factor: 60.716

5.  mTOR and HIF-1alpha-mediated tumor metabolism in an LKB1 mouse model of Peutz-Jeghers syndrome.

Authors:  David B Shackelford; Debbie S Vasquez; Jacqueline Corbeil; Shulin Wu; Mathias Leblanc; Chin-Lee Wu; David R Vera; Reuben J Shaw
Journal:  Proc Natl Acad Sci U S A       Date:  2009-06-18       Impact factor: 11.205

6.  Evaluating response to metformin/cisplatin combination in cancer cells via metabolic measurement and clonogenic survival.

Authors:  Sang Hyeok Woo; Vlad C Sandulache; Liangpeng Yang; Heath D Skinner
Journal:  Methods Mol Biol       Date:  2014

7.  Glycolytic inhibition alters anaplastic thyroid carcinoma tumor metabolism and improves response to conventional chemotherapy and radiation.

Authors:  Vlad C Sandulache; Heath D Skinner; Yuan Wang; Yunyun Chen; Cristina T Dodge; Thomas J Ow; James A Bankson; Jeffrey N Myers; Stephen Y Lai
Journal:  Mol Cancer Ther       Date:  2012-05-09       Impact factor: 6.261

8.  THE METABOLISM OF TUMORS IN THE BODY.

Authors:  O Warburg; F Wind; E Negelein
Journal:  J Gen Physiol       Date:  1927-03-07       Impact factor: 4.086

Review 9.  Review of aerobic glycolysis and its key enzymes - new targets for lung cancer therapy.

Authors:  Xue-Bing Li; Jun-Dong Gu; Qing-Hua Zhou
Journal:  Thorac Cancer       Date:  2015-01-07       Impact factor: 3.500

10.  Quinoline 3-sulfonamides inhibit lactate dehydrogenase A and reverse aerobic glycolysis in cancer cells.

Authors:  Julia Billiard; Jennifer B Dennison; Jacques Briand; Roland S Annan; Deping Chai; Mariela Colón; Christopher S Dodson; Seth A Gilbert; Joel Greshock; Junping Jing; Hong Lu; Jeanelle E McSurdy-Freed; Lisa A Orband-Miller; Gordon B Mills; Chad J Quinn; Jessica L Schneck; Gilbert F Scott; Anthony N Shaw; Gregory M Waitt; Richard F Wooster; Kevin J Duffy
Journal:  Cancer Metab       Date:  2013-09-06
View more
  1 in total

Review 1.  Metabolic Reprogramming of Thyroid Cancer Cells and Crosstalk in Their Microenvironment.

Authors:  Lisha Bao; Tong Xu; Xixuan Lu; Ping Huang; Zongfu Pan; Minghua Ge
Journal:  Front Oncol       Date:  2021-12-02       Impact factor: 6.244

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.